Polyrizon appoints dr. michal meir as senior director of regulatory and clinical affairs

Raanana, israel, dec. 19, 2024 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the "company" or "polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of dr. michal meir, senior consultant at medtech sme ltd., as senior director of regulatory and clinical affairs. the appointment was made as part of the company's preparations towards its clinical trial for pl-14 that is expected to commence in 2025. dr. meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product development.
PLRZ Ratings Summary
PLRZ Quant Ranking